EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: Mechanism and therapeutic implications
Loading...
Download
Associated Records
File Licence
Editors
Date
2015-10-08
Source Title
Oncogene
Journal Title
Journal ISSN
Volume Title
Publisher
NATURE PUBLISHING GROUP
Melbourne Authors
Affiliation
Medical Biology (W.E.H.I.)
Obstetrics and Gynaecology
Sir Peter MacCallum Department of Oncology
Obstetrics and Gynaecology
Sir Peter MacCallum Department of Oncology
Document Type
Journal Article
Subject Code
Citation
Greenall, S. A., Donoghue, J. F., Van Sinderen, M., Dubljevic, V., Budiman, S., Devlin, M., Street, I., Adams, T. E. & Johns, T. G. (2015). EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: Mechanism and therapeutic implications. Oncogene, 34 (41), pp.5277-5287. https://doi.org/10.1038/onc.2014.448.
Access Status
Access this item via the Open Access location
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain cancer. EGFRvIII is tumorigenic, in part, through its transactivation of other receptor tyrosine kinases (RTKs). Preventing the effects of this transactivation could form part of an effective therapy for glioma; however, the mechanism by which the transactivation occurs is unknown. Focusing on the RTK MET, we show that MET transactivation in U87MG human glioma cells in vitro is proportional to EGFRvIII activity and involves MET heterodimerization associated with a focal adhesion kinase (FAK) scaffold. The transactivation of certain other RTKs was, however, independent of FAK. Simultaneously targeting EGFRvIII (with panitumumab) and the transactivated RTKs themselves (with motesanib) in an intracranial mouse model of glioma resulted in significantly greater survival than with either agent alone, indicating that cotargeting these RTKs has potent antitumor efficacy and providing a strategy for treating EGFRvIII-expressing gliomas, which are usually refractory to treatment.